(Bloomberg) Biogen Inc. fell the most in two years as its latest foray into Alzheimer’s disease got off to a slow start, suggesting a long road to growth for the biotechnology giant.Most Read from BloombergMusk Says Putin Can’t Lose in Ukraine, Opposes Senate BillS&P 500 Set for Worst CPI Day Since September 2022: Markets WrapPutin Seeks Revenge on a World Order He Once Wanted to JoinRetail Traders Are Losing Billions in India’s Booming Options MarketTrump Asks Supreme Court to Keep DC Electi
Researchers found that if the mitochondria (the cellular powerplant) shows an increase in metabolic rate, it could be a telltale indicator of Alzheimer's disease. TheHealthSite.com